Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaji Kumar

Showing results (251-260 of 516) with videos related to

Pageof 52
Sort By:
Transplantation and Cellular Therapy|April 10, 2021
Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple MyelomaHarsh Parmar, Abdullah S Al Saleh, Alissa Visram, et al.
British Journal of Haematology|November 29, 2024
Autologous stem cell transplantation for multiple myeloma patients whose myeloma-defining event was SLiMIuliana Vaxman, Shaji Kumar, Inbar Cohen, et al.
Oncogene|March 1, 2005
Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitorsTeru Hideshima, Dharminder Chauhan, Kenji Ishitsuka, et al.
Blood|June 16, 2011
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myelomaSumit Madan, Martha Q Lacy, Angela Dispenzieri, et al.
Leukemia & Lymphoma|May 10, 2018
Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myelomaShaji Kumar, Brian Durie, Hareth Nahi, et al.
American Journal of Hematology|October 1, 2011
Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myelomaGuner Hayri Ozsan, Ivana N Micallef, Angela Dispenzieri, et al.
Blood|February 12, 2005
Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivoMakoto Hamasaki, Teru Hideshima, Pierfrancesco Tassone, et al.
JACC. Advances|January 20, 2026
Spinal Stenosis and Carpal Tunnel Syndrome as Surrogates of Transthyretin Amyloid CardiomyopathyLaura De Michieli, Susan Geyer, Ellen McPhail, et al.
British Journal of Haematology|September 10, 2011
Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03Susanna J Jacobus, Shaji Kumar, Hajime Uno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2018
Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over TimeM Hasib Sidiqi, Mohammed A Aljama, Francis K Buadi, et al.
Pageof 52

Showing results (251-260 of 516) with videos related to

Sort By:
Pageof 52
Transplantation and Cellular Therapy|April 10, 2021
Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple MyelomaHarsh Parmar, Abdullah S Al Saleh, Alissa Visram, et al.
British Journal of Haematology|November 29, 2024
Autologous stem cell transplantation for multiple myeloma patients whose myeloma-defining event was SLiMIuliana Vaxman, Shaji Kumar, Inbar Cohen, et al.
Oncogene|March 1, 2005
Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitorsTeru Hideshima, Dharminder Chauhan, Kenji Ishitsuka, et al.
Blood|June 16, 2011
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myelomaSumit Madan, Martha Q Lacy, Angela Dispenzieri, et al.
Leukemia & Lymphoma|May 10, 2018
Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myelomaShaji Kumar, Brian Durie, Hareth Nahi, et al.
American Journal of Hematology|October 1, 2011
Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myelomaGuner Hayri Ozsan, Ivana N Micallef, Angela Dispenzieri, et al.
Blood|February 12, 2005
Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivoMakoto Hamasaki, Teru Hideshima, Pierfrancesco Tassone, et al.
JACC. Advances|January 20, 2026
Spinal Stenosis and Carpal Tunnel Syndrome as Surrogates of Transthyretin Amyloid CardiomyopathyLaura De Michieli, Susan Geyer, Ellen McPhail, et al.
British Journal of Haematology|September 10, 2011
Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03Susanna J Jacobus, Shaji Kumar, Hajime Uno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2018
Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over TimeM Hasib Sidiqi, Mohammed A Aljama, Francis K Buadi, et al.
Pageof 52